Acumen reports Q1 net loss of $14.9M; Phase 2 sabirnetug trial initiated

Acumen Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.25

Net loss of $14.9M for Q1 2024 vs. $11.3M in Q1 2023; R&D expenses rose to $12.4M.
Cash, equivalents and marketable securities totaled $296.6M as of March 31, 2024; expected to fund operations into H1 2027.
First patient dosed in ALTITUDE-AD Phase 2 study of sabirnetug for early Alzheimer's in May 2024.
Phase 1 subcutaneous dosing study of sabirnetug expected to start mid-2024; Lonza collaboration for manufacturing announced.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported first quarter of 2024 results: net income $14.9 million.

Period: first quarter of 2024
Net income: $14.9 million
Result: reported results

Exact text from the filing

Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended March 31, 2024.

View on SEC.gov

Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-24-000061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.